Sat Kartar Life Limited (NSE: SATKARTAR) is a New Delhi, Delhi-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹256 Cr, it ranks #2,445 by market cap among the 6,197 Indian listed companies on FinBizNet, and #7 of 9 in Non-Prescription Drugs. The share price was ₹170.90 as of 16 Nov 2026.
| Current Price | ₹170.90 |
|---|---|
| Market Cap | ₹256 Cr |
| NSE Symbol | SATKARTAR |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 15.7 |
| Return on Equity | 25.30% |
| Return on Assets | 17.82% |
| Beta (1Y) | 0.71 |
| Dividend Yield | 0.41% |
| Headquarters | New Delhi, Delhi |
| Website | www.satkartar.in |
Promoters held 63.49% of Sat Kartar Life Limited's shares as of Sept 2026, against 63.43% in Sept 2025 (+0.06 percentage points).
Sat Kartar Life Limited, an ayurvedic healthcare company, provides ayurvedic products in India. The company offers ayurvedic products, vitamins, supplements, and herbal products for various health conditions, including piles, diabetes, sexual health, stamina booster, immunity booster, infertility, joint pain, hair care, addiction care, and respiratory health solutions. It also sells its products through online. The company was formerly known as Sat Kartar Shopping Limited and change its name to Sat Kartar Life Limited in February 2026. The company was incorporated in 2012 and is based in New Delhi, India.
1. Herbal Products-This segment offers ayurvedic products related to personal wellness of men and women; and products related to address various diseases, such diabetes, addiction, joint pain, low immunity, and others. 2. NA-NA 3. NA-NA 4. NA-NA
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹44,982 Cr | 43.4 | 48.91% | ₹1,184 Cr | +3.3% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹20,245 Cr | 30.5 | 12.36% | ₹2,603 Cr | +11.7% |
| Bliss Gvs Pharma Ltd. | ₹6,817 Cr | 53.9 | 11.60% | ₹313 Cr | +426.3% |
| Zota Health Care Ltd | ₹4,585 Cr | n/m | -16.05% | ₹199 Cr | -15.1% |
| Amrutanjan Health Care Ltd. | ₹1,467 Cr | 25.3 | 16.62% | ₹135 Cr | -28.1% |
| Jenburkt Pharmaceuticals Ltd. | ₹433 Cr | 12.5 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹256 Cr | 15.7 | 25.30% | — | — |
| Vista Pharmaceuticals Ltd. | ₹40 Cr | n/m | -10.82% | — | -37.1% |
| Welcure Drugs & Pharmaceuticals | ₹23 Cr | n/m | -5.50% | — | -64.2% |
Listed by market capitalisation. Ratios are shown for context only.
Sat Kartar Life Limited is trading at ₹170.90, with a market capitalisation of ₹256 Cr.
Sat Kartar Life Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Sat Kartar Life Limited has a P/E of 15.7 and a return on equity of 25.30%.
Sat Kartar Life Limited is listed on the NSE under the symbol SATKARTAR.
Promoters held 63.49% of Sat Kartar Life Limited's shares as of Sept 2026, against 63.43% in Sept 2025 (+0.06 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.